key: cord-0789018-dieanwry authors: Samidoust, Pirouz; Esmaeili Delshad, Mohammad Sadegh; Talemi, Mostafa Navid; Mojtahedi, Kourosh; Samidoust, Aryan; Jahangiri, Soghra; Ashoobi, Mohammad Taghi title: Incidence, characteristics, and outcome of COVID-19 in patient on liver transplant program: a retrospective study in north of Iran date: 2021-09-03 journal: New Microbes New Infect DOI: 10.1016/j.nmni.2021.100935 sha: 4898ea97315aa11834149c4baffbe0319c1d8d55 doc_id: 789018 cord_uid: dieanwry The risk of severe coronavirus disease-2019 (COVID-19) disease seems to be higher in individuals with solid organ transplantation. Therefore, the purpose of the present research is investigating the incidence of COVID-19 and laboratory data and epidemiologic factors in liver transplant recipients and the patients on the waiting list for liver transplantation. In this study, we evaluated the records of patients on the waiting list for liver transplantation and recipients of liver transplant. Demographic data, underlying disease, history of drug use and participants’ outcomes were collected. The diagnosis of SARS-CoV-2 infection for all patients was confirmed using a nasopharyngeal swab specimen with real-time RT-PCR. During the study period, 172 patients were enrolled, among whom 85 patients (49.4%) were on the waiting list for liver transplantation and 87 patients (50.6%) were recipients of liver transplant. Out of them, 10 (5.8%) had a positive result for SARS-CoV-2. Of these patients, 7.05% (6/85) and 4.6% (4/87) of patients on the waiting list and recipients of liver transplant were positive for SARS-CoV-2, respectively. Patients on the waiting list with COVID-19 infection had higher median of albumin, ALT, AST, TBIL, DBIL, HDL and LDL value. In summary, the incidence of COVID-19 in liver transplant patients was slightly high. The existence of underlying liver diseases should be well known as one of the poor predictive factors for worse outcomes in patients with COVID-19. So, comparative studies are recommended to identify risk factors for COVID-19 in patients with liver injury. coronavirus disease-2019 (COVID- 19) , initially observed in Wuhan, China in 2019. It has had a quick spread in the 27 world. In a similar way to this family's previous members, COVID-19 generally results in respiratory tract infection 28 that might be severe, asymptomatic, or mild (1-4). The main symptoms of this disease include fatigue, fever, dry 29 cough, and sometimes nausea, shortness of breath, vomiting, and diarrhea. As preliminary data indicates, the severity 30 of disease has some predictors, such as hypertension, old age, diabetes mellitus, chronic liver and kidney disease, and 31 coronary artery disease (5-8). The severity of the disease is mild in most patients, still, the risk of severe COVID-19 32 disease seems to be higher in individuals with solid organ transplantation, like liver transplants, due to receiving 33 lifetime immunosuppressive therapy and their chronic immunosuppressed state (6, 9). Since the angiotensin-converting enzyme-2 (ACE2) receptor is present in the biliary epithelial and liver cells, the liver 35 has been identified as a potential target for COVID-19 infection. Liver enzymes' elevation is a presentation of this 36 disease that is mainly observed in those admitted in the hospital with an incidence range of 14-53.1% (10). The range of case-fatality rate from COVID-19 is extensive as 1-7.2%, despite the rate appearing much higher for 38 recipients of solid organ transplants (9). Nevertheless, the COVID-19 outcomes and epidemiology among recipient's 39 liver transplanted are confined to case series and case reports (11). There are few early descriptive case series and case 40 reports of recipients solid organ transplantation (SOT) suffering from COVID-19, suggesting poor outcomes. However, it is not known that whether it is different from COVID-19 in the non-transplant population (11-14). Various 42 interventions were conducted in recipients of liver with COVID-19, such as withdrawal and reduction of 43 immunosuppression, treating with empirical anti-viral agents like lopinavir/ritonavir, chloroquine, umifenovir, and 44 remdesivir, and high-dose glucocorticoids (15, 16). Thus, more all-embracing research is required for defining 45 potential risk factors in patients with underlying liver diseases for the development of severe COVID-19. The purpose of the present research is investigating the incidence of COVID-19 and laboratory data and epidemiologic factors in liver transplant recipients and the patients on the waiting list for liver transplantation admitted to referral Demographic data and variable as categorical variables were described as frequencies and percentages. The mean and 67 standard deviation (SD) were carried out to describe continuous variables and qualitative data. All analyses were 68 conducted using SPSS version 18. During the study period, 172 patients were enrolled, among whom 85 patients (49.4%) were on the waiting 71 list for liver transplantation and 87 patients (50.6%) were recipients of liver transplant. The mean age of patients was 72 47 ± 15.2. The male subjects were 49 (57.6%) on the waiting list for liver transplantation and 59 (67.8%) in recipients list and one from recipients of liver transplant . The demographics and details of underlying disease are shown in Table 85 1. Table 2 . As shown in Table 3 , history of drug use in liver transplant patients infected with COVID-19 was more than patients 95 on the waiting list. The details of medication history among transplanted and patients on the waiting list for liver 96 transplantation without and with COVID-19 are shown in Table 3 . Since ACE2 enzyme has a proven role in the pathogenicity of COVID-19 and due to the plentiful production of this 99 enzyme in hepatic and biliary epithelial cells, the liver is considered as a target organ for this virus (17-19). The Centers for Disease Control and Prevention (CDC) has stated that patients older than 65 years, and those with 101 liver diseases are at higher risk of fatal disease (20), therefore, regarding to insufficient data on chronic liver diseases 102 and patients with liver transplantation during the COVID-19 pandemic in our region , the aim of the present study was 103 a descriptive study of the incidence and mortality rate of COVID-19 in liver transplant recipients and the patients on 104 the waiting list for liver transplantation. The results of this study showed that 5.8% of patients developed COVID-19 disease, and their mortality was of 20%. recipients should be considered as population at risk (21-23). The incidence of COVID-19 in patients with liver transplantation especially in men over the age of 45 years was In addition, in a meta-analysis study, the relationship between liver damage and the severity of COVID-19 infection and albumin value were high in liver transplant patients with COVID-19. In addition, patients on the waiting According to studies, liver damage observed in patients with COVID-19 may be due to Lopinavir/ritonavi, which is 124 used as an antiviral drug to treat SARS-CoV-2 infection (29). In conclusion, the results of the present study showed that the incidence of COVID-19 in liver transplant patients was J o u r n a l P r e -p r o o f Emerging coronaviruses: first SARS, 187 second MERS and third SARS-CoV-2: epidemiological updates of COVID-19. Le infezioni in 188 medicina Aptamers, the bivalent agents as probes and therapies for 190 coronavirus infections: A systematic review The sound of getting rid of coronavirus by RNA interference 192 technology: RNAi against COVID-19 Functional 194 and Structural Characterization of SARS-Cov-2 Spike Protein: An In Silico Study A narrative literature review on 197 traditional medicine options for treatment of corona virus disease Information about the new coronavirus disease (COVID-19). Radiol Bras A light shining through darkness: probiotic against 202 COVID-19 The role of proteases in the invasion of SARS-CoV-2 virus into human Clinical Manifestations and 213 Characterization of COVID-19 in Liver Transplant Recipients: A Systematic Review of Case 214 Reports and Case Series Clinical Presentation, Treatment, and 216 Mortality Rate in Liver Transplant Recipients With Coronavirus Disease 2019: A Systematic 217 Review and Quantitative Analysis Impact of the COVID-219 19 pandemic on liver donation and transplantation: A review of the literature. World journal of 220 gastroenterology COVID-224 19 in solid organ transplant recipients: A single-center case series from Spain. American journal of 225 transplantation : official journal of the American Society of Transplantation and the American 226 Society of Transplant Surgeons A mini-review of the 228 validity, quality and efficacy of candidate vaccines in controlling the COVID-19 Disease-2019 (COVID -19): A Case Report Cleaning and disinfection for community facilities Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients Clinical 246 characteristics and outcomes of COVID-19 in solid organ transplant recipients: A cohort study American journal of transplantation : official journal of the American Society of Transplantation 248 and the American Society of Transplant Surgeons Impact of COVID-250 19 on liver transplant recipients-A systematic review and meta-analysis The Impacts of the COVID-19 Pandemic on Liver Transplant Patients Risk of hepatic failure in COVID-19